Drug intelligence / Profile preview

OptPA

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes
Administration: Intracerebral

Overview

OptPA is an optimized variant of recombinant tissue-type plasminogen activator (rtPA) engineered to improve the efficacy and safety of thrombolytic therapy for intracerebral hemorrhage (ICH). It is designed to be non-neurotoxic, unlike conventional rtPA, and exhibits a decreased capacity to convert plasminogen into plasmin, thereby reducing potential bleeding events while maintaining similar fibrinolytic activity to rtPA. OptPA is a key component of O2L-001, a formulation designed for extended release to achieve high thrombolysis efficacy in ICH evacuation.

Other names: optimized tPAoptimized tissue-type plasminogen activatorW253R/R275S recombinant tissue-type plasminogen activator

Targets

PLG (Plasminogen)Fibrin (Factor Ia)

Beyond the preview

Go deeper on OptPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OptPA.

Explore the full profile